OncoMatch/Clinical Trials/NCT07278986
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Is NCT07278986 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including CYTALUX™ (pafolacianine) and 1788 4K Camera System with Advanced Imaging Modality for endometrial cancer.
Treatment: CYTALUX™ (pafolacianine) · 1788 4K Camera System with Advanced Imaging Modality — The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania
- University of Pennsylvania Gynecologic Oncology Department · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07278986 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages